Wittes Re
About
In The Last Decade
Wittes Re
24 papers receiving 336 citations
Peers
Comparison fields: 5 of 71
- Oncology 215
- Epidemiology 112
- Molecular Biology 87
- Pulmonary and Respiratory Medicine 71
- Hematology 42
Countries citing papers authored by Wittes Re
This map shows the geographic impact of Wittes Re's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wittes Re with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wittes Re more than expected).
Fields of papers citing papers by Wittes Re
This network shows the impact of papers produced by Wittes Re. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wittes Re. The network helps show where Wittes Re may publish in the future.
Co-authorship network of co-authors of Wittes Re
This figure shows the co-authorship network connecting the top 25 collaborators of Wittes Re. A scholar is included among the top collaborators of Wittes Re based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wittes Re. Wittes Re is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 18 | |
| 2 | Factor VIII:C purified from plasma via monoclonal antibodies: human studies. | 10 |
| 3 | Paying for patient care in treatment research--who is responsible? | 12 |
| 4 | Methodology for the rational development of methotrexate analogs in the clinic. | 1 |
| 5 | Policy on monitoring and reporting results. | 1 |
| 6 | Unresolved issues in combination chemotherapy. | 30 |
| 7 | Low-grade non-Hodgkin's lymphomas revisited. | 7 |
| 8 | Adjuvant chemotherapy--clinical trials and laboratory models. | 9 |
| 9 | Site visit monitoring program of the clinical cooperative groups: results of the first 3 years. | 11 |
| 10 | Phase I and clinical pharmacological evaluation of 4'-deoxydoxorubicin in patients with advanced cancer. | 17 |
| 11 | The phase II trial. | 17 |
| 12 | Alternating combination chemotherapy regimens in small-cell lung cancer. | 16 |
| 13 | Phase II trial of mitoguazone in patients with advanced head and neck cancer. | 5 |
| 14 | Phase II trial of 4'-epi-doxorubicin in patients with advanced malignant melanoma. | 8 |
| 15 | Phase II trial of 4'-epi-doxorubicin in patients with non-small cell lung cancer. | 19 |
| 16 | A phase II trial of m-AMSA in patients with small-cell lung cancer. | 6 |
| 17 | Phase II trial of pyrazofurin in advanced head and neck cancer. | 3 |
| 18 | Phase II evaluation of pyrazofurin in patients with carcinoma of the lung. | 8 |
| 19 | Trial of hydrazine sulfate (NSC-150014) in patients with cancer. | 16 |
| 20 | Oat cell carcinoma of the lung. | 127 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.